About Us

TICEBA is a highly innovative German bio-pharmaceutical Life-Science Company, which operates in the fields of stem cell research and regenerative medicine.

As the world's first private tissue bank, the German company offers its clients the removal and storage of the cells from the skin and the stem cells contained therein as personal, biological life insurance and has established itself as a pharmaceutical active ingredient manufacturer for stem cell-based therapies. TICEBA produces high quality stem cells as a drug (§13 AMG) for the clinical trials conducted by its affiliated daughter company RHEACELL GmbH & Co. KG.

TICEBA - Company - Picture 01TICEBA - Company - Picture 02

TICEBA conducts the sampling and long term storage of the cells from the skin and the stem cells contained therein based on its own research. International research findings are taken into account and the highest international standards are met.

TICEBA is the first tissue bank worldwide to offer its customers the personal and individual storage of skin tissue and the stem cells contained therein - as unique, valuable health care measure at the highest level and in accordance with the latest findings of science and technology.

News
Coronavirus and Mesenchymal Stem Cells

Therapy for Pneumonia Patients infected by 2019 Novel Coronavirus

Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)

Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus

Article about our study with limbal stem cells

On the website of the Harvard Stem Cell Institute you will find the following news release about the ongoing clinical trial conducted by our daughter company RHEACELL in patients suffering from limbal stem cell deficiency: Restoring vision: A stem cell therapy for cornea regeneration reaches the clinical-trial stage.

Clinical Trial - EB

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and several European competent national regulatory authorities. The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) for the treatment of EB.

Clinical Trial - LSCD

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and the German regulatory authority (Paul Ehrlich Institute). The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) and Fast Track designation from the FDA for the treatment of LSCD.

Safety

In a comprehensive preclinical study program, safety and local tolerability of ABCB5+ MSCs following subcutaneous, intramuscular and intravenous application has been demonstrated (Tappenbeck et al., 2019).

Newsletter